On Dec. 10, 2021, Moderna announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to accelerate supply of 20 million doses to COVAX by December 31, 2021 for a total of 54 million doses made available to COVAX in 2021. Deliveries to COVAX Advance Market Commitment (AMC) countries have already begun.

These doses included in Moderna’s the previously announced agreement with Gavi and were originally scheduled for delivery in the first quarter of 2022. Given the acceleration into 2021, Moderna expected to supply up to 96.5 million doses in the first quarter of 2022 and an additional 116.5 million doses in the second quarter of 2022. Gavi retained the option to procure 233 million additional doses in 2022 under the original agreement.

Moderna also announced a new supply agreement with Gavi for an additional 20 million doses for delivery in the second quarter of 2022 for a total of up to 136.5 million doses in the second quarter of 2022. Together, these two agreements allow Gavi to purchase up to 650 million doses of the Moderna COVID-19 vaccine for delivery through 2022.